

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Suzhou Basecare Medical Corporation Limited**  
**蘇州貝康醫療股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 2170)**

**INSIDE INFORMATION ANNOUNCEMENT**  
**CESSATION OF THE H SHARE FULL CIRCULATION PROGRAMME**

This announcement is made by Suzhou Basecare Medical Corporation Limited (the “**Company**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the laws of Hong Kong).

References are made to the announcements of the Company dated August 20, 2021, February 24, 2022, March 6, 2022 and September 9, 2022 (the “**Announcements**”) in relation to the Company’s participation in the H Share full circulation programme. Unless otherwise defined, capitalised terms used herein shall have the same meanings as those defined in the Announcements.

**CESSATION OF THE H SHARE FULL CIRCULATION PROGRAMME**

Taking into account the overall situation of the capital market and communication with the relevant Participating Shareholders, pursuant to the resolution of the board of directors (the “**Directors**”) of the Company (the “**Board**”) passed on November 16, 2022, the Company has decided not to further proceed with the H Share full circulation programme (the “**Cessation of the H Share Full Circulation Programme**”).

## SHAREHOLDING STRUCTURE

The share capital structure of the Company as of the date of this announcement is set out below:

<b>Class of shares</b>	<b>Number of shares</b>	<b>Approximate percentage</b>
Domestic shares	183,181,817	66.97%
Unlisted foreign shares	7,630,348	2.79%
H Shares	82,713,835	30.24%
<b>Total</b>	<b><u>273,526,000</u></b>	<b><u>100.00%</u></b>

The Cessation of the H Share Full Circulation Programme will not have any material adverse impact on the operations or financial performance of the Company.

**Shareholders of the Company and potential investors are advised to exercise caution when dealing in the securities of the Company.**

By order of the Board  
**Suzhou Basecare Medical Corporation Limited**  
**Dr. Liang Bo**  
*Chairman and General Manager*

Suzhou, PRC, November 16, 2022

*As of the date of this announcement, the Board comprises Dr. LIANG Bo, Mr. KONG Lingyin and Ms. YANG Ying as executive Directors; Mr. XU Wenbo, Mr. ZHANG Jiecheng and Mr. WANG Weipeng as non-executive Directors; and Dr. KANG Xixiong, Dr. HUANG Taosheng and Mr. CHAU Kwok Keung as independent non-executive Directors.*